Sarepta Therapeutics (NASDAQ: SRPT ) �won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer.� Its one potential challenger on the scene, Prosensa, recently announced plans to move forward with an initial public offering. Here are three views on what a Prosensa IPO could mean for Sarepta.
Negative
Prosensa's IPO won't have much impact on the progress of its DMD drug, drisapersen. The Dutch biotech didn't need to raise money to keep development going for the drug. GlaxoSmithKline (NYSE: GSK ) obtained rights to drisapersen back in 2009 and funds the development effort. Similarly, Prosensa doesn't really�need to worry about footing the bill for commercialization of the drug, assuming it ultimately gains regulatory approval. Glaxo will also handle the finances there.
A publicly traded Prosensa doesn't threaten Sarepta any more than it would as a privately held company. However, it could possibly have a negative impact on Sarepta's shares. How? Investors could decide to hedge their bets by buying Prosensa shares (when available) rather than buying more Sarepta stock. This would lessen demand for Sarepta to some extent. Weaker demand would serve as a drag on the stock, keeping it from rising as high as it could reach.
Top Heal Care Stocks To Watch For 2014: MedCAREERS Group Inc (MCGI)
MedCareers Group, Inc., incorporated on December 30, 2004, focus is to develop and build value through its wholly owned subsidiary Nurses Lounge (www.nurseslounge.com), an online professional network and communication source for nurses and organizations connected to the nursing community. On August 10, 2010, MedCareers acquired the workabroad.com Website from Steve Elisberg (Workabroad.com Website).
The Nurses Lounge is a professional network for nursing professionals providing relevant content and information and professional networking. Nurses can subscribe to Lounges created by nursing schools, nurse associations, employers, specialties and more to receive email updates of relevant news, events and other info. Professional networking is a place for nurses to connect with colleagues and network on a professional level.
Advisors' Opinion:- [By Peter Graham]
While small cap green or renewable energy type of stocks have been the flavor of the month for many stock promoters (and sometimes still are), small cap health care stocks like PPJ Enterprise (OTCMKTS: PPJE), Plantation Development Corp (OTCMKTS: BRMA) and MedCAREERS Group Inc (OTCMKTS: MCGI) have also started to get some notice lately ��perhaps because Obamacare has been topping the news lately. However, are these small cap health care stocks a better bet for investors or for their promoters? Here is a quick reality check and a checkup:
Top Heal Care Stocks To Watch For 2014: Analytica Bio - Energy Corp (ABEC)
Analytica Bio-Energy Corp., formerly Uniwell Electronic Corporation, incorporated on January 12, 2004, is a company with water purification system. The Company was a shell company.
The Company focused on acquiring an active business. In September 2013, the Company changed its name to Analytica Bioenergy, Inc.
Advisors' Opinion:- [By Dan Burrows]
Most importantly, on days when this penny stock did see heavy volume, it tumbled — a classic red flag for the “dump” part of pump-and-dump schemes, which penny stocks are ripe for.
Top Penny Stocks: Analytica Bio-Energy Corp. (ABEC)YTD Performance: 29,300%
52-Week Range: $0.0017 – $0.50
Average Volume (3 months): 9,574
Market Cap: $10.6 million
Best Asian Stocks To Buy For 2014: Harte-Hanks Inc. (HHS)
Harte-Hanks, Inc., a direct and targeted marketing company, provides multichannel direct and digital marketing services, and shopper advertising opportunities to a range of local, regional, national, and international consumer and business-to-business marketers in the United States and other countries. It offers integrated, multichannel, and data-driven solutions for various brands to retail, high-tech/telecom, financial services, and pharmaceutical/healthcare markets. The company provides agency and digital services, including Website development and design, digital strategy, social media marketing and monitoring, email marketing, and ecommerce and interactive relationship management services; database marketing solutions that enable organizations to build and manage customer communication strategies; and Trillium Software System, a global locator geocoding product, as well as associated data governance services. It also offers direct mail and fulfillment, and business-to -business lead generation services, as well as operates teleservice workstations that provide advanced contact center solutions. The company has a strategic partnership with GX Software. Harte-Hanks, Inc. was founded in 1970 and is headquartered in San Antonio, Texas.
Advisors' Opinion:- [By Eric Volkman]
There will soon be a new moniker on the CEO nameplate at Harte-Hanks (NYSE: HHS ) . The company has picked Robert Philpott to replace outgoing Chief Executive Larry Franklin, who will retire on June 30. Philpott, who was selected following a global search led by a board of directors committee, will also assume Franklin's role as president of the company.
- [By Luke Jacobi]
Harte-Hanks (NYSE: HHS) shot up 6.76 percent to $8.53 after BMO Capital upgraded the stock from Market Perform to Outperform.
Facebook (NASDAQ: FB) gained 3.78 percent to $51.04. Facebook's Instagram reported that it will introduce advertisements in the coming months. Sterne Agee raised the price target on the stock from $50.00 to $58.00.
Top Heal Care Stocks To Watch For 2014: S.Y. Bancorp Inc.(SYBT)
S.Y. Bancorp, Inc. operates as the bank holding company for Stock Yards Bank & Trust Company that provides commercial and personal banking services in Louisville, Kentucky; southern Indiana and Indianapolis, Indiana; and Cincinnati, Ohio. Its deposits consist of non-interest and interest bearing demand deposits, savings deposits, certificates of deposit, individual retirement accounts, money market deposits, and time deposits. The company provides various secured loans, including commercial lines of credit, commercial term loans, real estate, construction, home equity, and consumer loans. It also offers wealth management services, including investment management, trust and estate administration, retirement planning, and financial planning services; securities brokerage services; and life insurance products, as well as originates and sells single-family residential mortgages. As of December 31, 2010, the company had 25 full service banking locations in the Louisville MSA, 2 full service banking locations in Indianapolis, and 3 full service banking locations in Cincinnati. S.Y. Bancorp, Inc. was founded in 1904 and is headquartered in Louisville, Kentucky.
Advisors' Opinion:- [By Marc Bastow]
Louisville-based bank holding company S.Y. Bancorp (SYBT) raised its quarterly dividend 5% to 21 cents per share, payable on Dec. 31 to shareholders of record as of Dec. 9.
SYBT Dividend Yield: 2.71%
Top Heal Care Stocks To Watch For 2014: Euromedis Groupe SA (EMG)
Euromedis Groupe SA is a France-based company that specializes in the design, manufacture, distribution, rental and export of medical and surgical equipment and products, and services for medical home care for hospitals, clinics, retirement homes, physicians, pharmacies, and individuals. The Company's product portfolio include products, such as syringes and needles; surgical equipment, such as catheters, instrumentation and compresses; gloves; hygiene products, comprising disposable clothing, masks and paper towel products, and pharmaceutical equipment, offering cotton wool and thermometers. Euromedis Groupe SA exports its products to Europe and Africa. Advisors' Opinion:- [By Sofia Horta e Costa]
Commodity producers increased as base metals rallied, with BHP Billiton Ltd. (BHP), the largest mining company, climbing 3.7 percent. Man Group (EMG) Plc soared 13 percent on a plan to redeem debt. Royal Bank of Scotland Group Plc dropped by the most in two months after Britain�� biggest state-owned lender reported operating profit that fell short of analysts��estimates.
- [By Sofia Horta e Costa]
Man Group Plc (EMG) jumped 6.8 percent to 104.3 pence. The world�� largest publicly traded hedge-fund manager said it no longer needs to hold a $300 million capital buffer after it confirmed with the U.K.�� Financial Conduct Authority a change in the company�� regulatory status.
- [By Inyoung Hwang]
Man Group Plc (EMG) advanced 3.6 percent to 85.85 pence. The world�� largest publicly traded hedge-fund manager posted its first quarterly net inflows in two years as clients added money to funds at its GLG Partners unit. Sales of Man Group�� funds totaled $4.1 billion in the third quarter, exceeding $3.4 billion of redemptions.
Top Heal Care Stocks To Watch For 2014: Perrigo Company PLC (PRGO)
Perrigo Company plc, incorporated on March 23, 1988, is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri. The Company�� businesses include Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, Life Sciences and Other Businesses. The Company offers Healthcare Products across a range of product categories primarily in the United States, the United Kingdom, Mexico, Israel and Australia, and distributes into dozens of other markets worldwide, including Canada, China and Latin America. In February 2014, the Company announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc.
The Company operates through several wholly owned subsidiaries. In the United States, its operations are conducted primarily through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., PBM Products, LLC, PBM Nutritionals, LLC, Paddock Laboratories, LLC, Perrigo Diabetes Care, LLC (formerly CanAm Care, LLC), Sergeant's Pet Care Products, Inc. and Fidopharm, Inc. Outside the United States, its operations are conducted primarily through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Galpharm Healthcare Ltd., Orion Laboratories Pty Ltd and Rosemont Pharmaceuticals Ltd.
Consumer Healthcare
Perrigo Consumer Healthcare (CHC) operation includes the Company's United States, United Kingdom and Mexico manufacturing operations supporting the sale of OTC pharmaceutical products. Perrigo CHC supplies more than 15 categories and 500 formulas and offers analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as w! ell as vitamins, dietary supplements and nutritional drinks. Perrigo offers a range of products, such advertised brand products as Tylenol, Advil or One-A-Day. Tylenol has acetaminophen as an active ingredient and is available in stores' analgesic (pain reliever) aisle. Store-brand acetaminophen is located next to the national brand, offering the same active ingredient (acetaminophen) and the same pain relief.
Perrigo Nutritionals
Perrigo is a manufacturer of nutrition products for the store brand market. Nutrition products include infant formula, pediatric nutritionals and vitamins, minerals, and supplements. Acquired by Perrigo, Perrigo Nutritionals, formerly PBM Products, LLC, had introduced private-label, or store-brand infant formulas to the United States. Perrigo Nutritionals is the supplier of store-brand infant formulas and nutrition products. With distribution to major retailers, Perrigo Nutritional products can be found in more than 40,000 retail locations around the world. Its pediatric nutritionals business extends its offerings to children well beyond infancy. Its baby cereals, toddler foods, and pediatric nutritional drinks are available as store brands at various retail locations throughout the United States and the international community. Perrigo manufactures a range of vitamins, minerals, and supplements, in every major segment of the business. Marketed under the store brand labels of the retailers in the food, drug, mass-merchandise and wholesale club channels, it manufactures over 395 formulas of dietary supplements. Its brands include Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex.
Rx Pharmaceuticals
The Company�� Rx Pharmaceuticals business is focused on the development, manufacture and sale of generic prescription drug products, primarily for the United States market. Manufacturing operations are based in the United States and Israel. Perrigo's portfolio focuses on complex, high-barrier ophthalmological, topical foam and or! al liquid! formulations. Its products include Acetylcysteine Injection 200 mg/mL (6g/30mL), Acetylcysteine Injection 6 g/30 mL (200 mg/1 mL), NOVAPLUS, ACTIDOSE with SORBITOL, ACTIDOSE-AQUA, ASPIRIN SUPPOSITORIES USP, Bacitracin Ophthalmic Ointment USP, Belladonna and Opium Suppositories C-II, BENZOIN COMPOUND TINCTURE USP, Benzoyl Peroxide 10% Acne Medication Wash, CLOBETASOL PROPIONATE LOTION 0.05% and Docusate Sodium.
Active Pharmaceutical Ingredients
Primarily through the Company�� Israel-based business, Perrigo develops, manufactures and markets the complex chemicals and active pharmaceutical ingredients used worldwide by the generic drug industry. Certain of these ingredients are also used in Perrigo's own pharmaceutical products. It manufactures API at facilities in Israel, India and China. Perrigo API specializes in tailor-made research and process development of APIs and Finished Dosage Forms (FDFs).
Life Sciences
Through the Company�� Israel-based business, Perrigo markets and manufactures branded prescription drugs and medical diagnostic products through exclusive agreements with pharmaceutical companies. Its Pharmaceutical and Medical Diagnostic Products businesses also market and manufacture branded prescription drugs under licenses. Other pharmaceutical and medical diagnostics products are imported to Israel through exclusive agreements. Products in life sciences segment include TYSABRI and ELND005. TYSABRI (natalizumab) is indicated for treatment of: Multiple Sclerosis: as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. TYSABRI is recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS therapy; Crohn�� Disease (CD): Inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn�� disease with e! vidence o! f inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor-伪.
Other
Perrigo's Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses. Other pharmaceutical and medical diagnostic products are imported to Israel through exclusive agreements with pharmaceutical and diagnostics companies. This business is divided into two departments: Pharma-Israel and Tayco Diagnostics. Pharma-Israel operates in the Israeli market as a partner in the marketing, sales and distribution of Rx (dermatology, gastroenterology, blood products, CNS, urology and other fields), OTC, generics, branded generics, dermo-cosmetics and dietary supplements. Tayco, the diagnostics division of Perrigo-Israel Pharmaceuticals Ltd., specializes in marketing and sales of medical laboratory systems, reagents, accessories and consumables. It also markets self-monitoring medical devices for diagnosis and treatment of diabetes. The division operates throughout Israel to service the central laboratory, hospital, clinic, point of care and self-testing markets. Its activities in the medical and research fields in Israel cover all market segments: medical (private and public health services), research institutions and the biotech industry.
The Company competes with Dr. Reddy�� Laboratories, Ltd., Actavis Inc., Aaron Industries, Inc., Ohm Laboratories, Inc., PL Developments, LNK International, Inc., Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber), Danone Baby Nutrition, Bayer AG, Pfizer, Inc., Rexall Sundown, Inc., Apotex, Glenmark Generics Inc., Impax, Prasco, Sandoz, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, and Zydus Pharmaceuticals.
Advisors' Opinion:- [By Laura Brodbeck]
Stocks moving in the Premarket included:
Boeing(NYSE: BA) lost 1.98 percent in premarket trade after falling 0.25 percent on Friday. Alcoa(NYSE: AA) fell 1.32 percent in premarket trade after gaining 3.58 percent last week. Perrigo Company PLC (NYSE: PRGO) gained 0.36 percent in premarket trade after rising 0.36 percent on Friday. Berkshire HathawayInc (NASDAQ: BRKB) gained 0.27 percent in premarket trade after increasing 5.95 percent last week.Earnings
- [By Holly LaFon]
Perrigo (PRGO) is a global manufacturer of over-the-counter (OTC) store brand and generic prescription pharmaceuticals, infant formulas, nutritional products and active pharma ingredients. The company is the dominant player in the OTC drug market with the largest distribution network and broadest range of product offerings. The OTC store brands have increased their market share by about 1-2% annually at the expense of national name product given their superior value proposition to both the consumer and retailers. Perrigo has numerous growth drivers over the next few years including the continued penetration of OTC store brands and introduction of new product categories. The stock sells at a reasonable valuation, in our opinion, given the company's strong management team, financial returns and long-term growth prospects.
- [By Ben Levisohn]
While the Paladin deal expands potential growth areas for the company, Endo�� business development focus remains on the heavily fragmented US market, where the company believes it can create the most value by operating acquired assets more efficiently. Management sees a robust pipeline of potential future deals and does not necessarily view other companies that benefit from a low tax rate [(Actavis (ACT), Perrigo (PRGO), Valeant Pharmaceuticals International (VRX))] as direct competitors for the assets it is targeting. We believe business development is likely to accelerate post the Paladin deal and the re-domicile to Ireland, and view Endo as in the early stages of its consolidation strategy…And with greater than $2 billion in capacity to do deals, we expect business development to accelerate.
Top Heal Care Stocks To Watch For 2014: Sensient Technologies Corp (SXT)
Sensient Technologies Corporation, incorporated on December 07, 1882, is a global manufacturer and marketer of colors, flavors and fragrances. Sensient uses advanced technologies at facilities around the world to develop specialty food and beverage systems, cosmetic and pharmaceutical systems, inkjet and specialty inks and colors, and other specialty and chemicals. The Company�� customers include international manufacturers representing some of the Known brands. The Company operates in two segments: Flavors & Fragrances Group and the Color Group. The Asia Pacific and the China Groups are included in the Corporate & Other category, along with the Company�� corporate expenses. The Company's principal products include: flavors, flavor enhancers and bionutrients; fragrances and aroma chemicals; dehydrated vegetables and other food ingredients; natural and synthetic food and beverage colors; cosmetic and pharmaceutical colors and additives; and technical colors, inkjet colors and inks, and specialty dyes and pigments.
Flavors & Fragrances Group
The Company is a developer, manufacturer and supplier of flavor and fragrance systems for the food, beverage, pharmaceutical, personal care and household-products industries. The Company�� flavor formulations are used in consumer products. Under the unified brand names of Sensient Flavors, Sensient Dehydrated Flavors and Sensient Fragrances, the Company is a supplier to multinational companies. The Flavors & Fragrances Group produces flavor and fragrance products, which impart a taste, texture, aroma and/or other characteristics to a range of consumer and other products. It includes the Company�� dehydrated flavors business, which produces ingredients for food processors. The products are systems products, including flavor-delivery systems, and compounded and blended products. In addition, the Company is engaged in selected ingredient products, such as essential oils, natural and synthetic flavors, and aroma chemicals. The Company ! serves food and non-food industries. In food industries, markets include savory, beverage, dairy, confectionery and bakery flavors. In non-food industries, the Company supplies fragrance products to the personal and home-care markets and supplies flavor products to the pharmaceuticals market.
Operating through the Company�� Sensient Dehydrated Flavors business, the Company is produces dehydrated onion and garlic products in the United States. The Company is also producers and distributors of chili powder, paprika, chili pepper and dehydrated vegetables, such as parsley, celery and spinach. Domestically, the Company sells dehydrated products to food manufacturers for use as ingredients and also for repackaging under private labels for sale to the retail market and to the food service industry. In addition, Sensient Dehydrated Flavors is dehydrators of specialty vegetables in Europe. The Flavors & Fragrances Group operates through the Company's subsidiaries Sensient Flavors LLC and Sensient Dehydrated Flavors LLC. The Company�� principal manufacturing plants are located in California, Illinois, Indiana, Michigan, Wisconsin, Belgium, Canada, the People�� Republic of China, France, Germany, Italy, Mexico, the Netherlands, Spain and the United Kingdom.
Color Group
The Company is a developer, manufacturer and supplier of colors for businesses globally. The Company provides natural and synthetic color systems for use in foods, beverages and pharmaceuticals; colors and other ingredients for cosmetics and pharmaceuticals, and technical colors for industrial applications and digital imaging. The Company sells its synthetic and natural colors to domestic and international producers of beverages, bakery products, processed foods, confections, pet foods, cosmetics and pharmaceuticals. The Company also makes inkjet inks and other dyes and pigments used in a variety of non-food applications.
The Color Group operates through the Company's subsidiary Sensient Col! ors LLC. ! Its principal manufacturing plants are located in California, Missouri, New Jersey, Brazil, Canada, Mexico, France, Germany, Hungary, Italy, Switzerland and the United Kingdom. The Color Group operates under trade names of Sensient Food Colors (food and beverage colors); Sensient Pharmaceutical Coating Systems (pharmaceutical colors and coatings); Sensient Cosmetic Technologies (cosmetic colors and ingredients and systems). and Sensient Industrial Colors (including paper colors; industrial colors for plastics, leather, wood stains, antifreeze and other uses; inkjet colors and inks; specialty inks, and display imaging).
Asia Pacific and China Groups
The Asia Pacific Group and the China Group focus on marketing the Company�� diverse product line in the Pacific Rim under the Sensient name. Through these operations, the Company offers a range of products from its Flavors & Fragrances Group and Color Group, as well as products developed by regional technical teams to appeal to local preferences. Sales, marketing and technical functions are managed through the Asia Pacific Group's headquarters in Australia. Manufacturing operations are located in Australia, Japan, New Zealand and the Philippines. The Asia Pacific Group maintains offices for research and development, as well as sales, in India, Indonesia, Korea, Singapore and Thailand.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Sensient Technologies (NYSE: SXT ) , whose recent revenue and earnings are plotted below.
Top Heal Care Stocks To Watch For 2014: Boston Scientific Corp (BSX)
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.
Interventional Cardiology
The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.
The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.
Cardiac Rhythm Management
The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.
Endoscopy
The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.
T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.
Peripheral Interventions
The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.
The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.
Urology/Women�� Health
The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.
The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.
Neuromodulation
The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.
Electrophysiology
The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.
The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.
Advisors' Opinion:- [By Holly LaFon]
The stocks he did buy in the fourth quarter are almost all large positions. The largest, Boston Scientific (BSX), is 5.4 percent of his portfolio. He bought 7,797,503 shares at an average price of $5.50. The stock has declined over 20 percent in the last year and 65 percent over the last five years. The company has had volatile free cash flow over the last ten years and declining annual revenue since 2007. However, it has cut expenses (including jobs), is investing in China, and is launching two dozen new devices in 2012, in an effort to increase earnings by double digits in the next five years. Year to date, the stock is up 12 percent.
- [By Dan Carroll]
Boston Scientific (NYSE: BSX ) hasn't been as quick to jump on the bandwagon as St. Jude and Medtronic have, but this cardiovascular-focused firm won't be left behind. Facing struggling sales from its CRM and interventional cardiology businesses, Boston Scientific pushed into renal denervation with its purchase of Vessix Vascular late last year. While Vessix's V2 renal denervation system has a long way to go before being approved in the U.S., it has already earned European and Australian regulatory approval.
- [By Dimitra DeFotis]
Colleague Dave Englander recommended taking profits in another medical device maker, Boston Scientific (BSX) in mid-August. At the time, he noted that stock was up 107% since his favorable recommendation had appeared, outpacing the Standard & Poor’s 500 Index by 80 points. He noted Boston Scientific faces competition from St. Jude and Medtronic (MDC), and he said that the market for stents and defibrillators has stabilized but is “not likely to grow meaningfully.” �(See “Time to Sell These Winners,” Aug. 14, subscription required.)
- [By Holly LaFon]
He added no new stocks to the low-turnover fund in the fourth quarter, but he did make several large increases. The stock positions he increased the most are: Hospira Inc. (HSP), CVS Caremark (CVS), Boston Scientific Corp. (BSX) and Zimmer Holdings Inc. (ZMH). Hospira (HSP)
Top Heal Care Stocks To Watch For 2014: Pacific Drilling SA (PACD)
Pacific Drilling S.A., incorporated on March 22, 2011, is an international offshore drilling Company. The Company is a provider of ultra-deepwater drilling services to the oil and natural gas industry through the use of high-specification drilling rigs. The Company�� primary business is to contract its ultra-deepwater drilling rigs, related equipment and work crews, primarily on a dayrate basis, to drill wells for its customers. The Company is primarily focused on the ultra-deepwater market. The Company generally consider ultra-deepwater to begin at water depths of more than 7,500 feet and to extend to the maximum water depths, in which rigs are capable of drilling, which is approximately 12,000 feet.
The Company operates four drillships and has four drillships under construction, two of which are under customer contract. In connection with the Restructuring, the Company�� Predecessor was contributed to a wholly owned subsidiary of the Company by a subsidiary of Quantum Pacific International Limited.
Advisors' Opinion:- [By Roberto Pedone]
Pacific Drilling (PACD) is an international offshore drilling contractor committed to becoming the preferred provider of ultra-deepwater drilling services to the oil and natural gas industry through the use of high-specification rigs. This stock closed up 1% to $9.94 in Thursday's trading session.
Thursday's Range: $9.87-$10.00
52-Week Range: $8.63-$10.99
Thursday's Volume: 450,000
Three-Month Average Volume: 308,772From a technical perspective, PACD bounced modestly higher here right above its 50-day moving average of $9.67 with above-average volume. This stock has been trending sideways and consolidating for the last five months, with shares moving between $8.89 on the downside and $10.23 on the upside. Shares of PACD are now starting to trend within range of triggering a breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if PACD manages to take out some key overhead resistance levels at $10.14 to $10.23 with high volume.
Traders should now look for long-biased trades in PACD as long as it's trending above its 50-day at $9.81 and then once it sustains a move or close above those breakout levels with volume that hits near or above 308,772 shares. If that breakout triggers soon, then PACD will set up to re-test or possibly take out its next major overhead resistance levels at $10.71 to its 52-week high at $10.99. Any high-volume move above $10.99 will then put its all-time high at $11.47 within range for shares of PACD.
- [By David Smith]
Chevron has been working hand-in-glove in implementing DGD with offshore rig operator Pacific Drilling (NYSE: PACD ) . Pacific's drillship Pacific Santa Ana was specifically built to Chevron's DGD-enhancing specifications and is working for the big company in the Gulf of Mexico.
- [By Aaron Levitt]
Management recently announced a hefty 50% hike in its quarterly dividend to 37.5 cents per share of NE stock. And with a 4.8% dividend yield, NE stock is now one of the best-paying dividend stocks in the energy sector.
Dividend Stocks To Buy #5 — Pacific Drilling (PACD)Estimated Dividend Yield: 6.5%
No comments:
Post a Comment